Guest User June 21, 2023 Brilacidin Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases
Guest User April 17, 2023 Brilacidin Innovation Pharmaceuticals’ Brilacidin Antifungal Research Published in Nature Communications
Guest User March 15, 2023 Brilacidin Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers
WKW December 13, 2022 Brilacidin Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin’s Potential for Treating Fungal Keratitis
Guest User November 15, 2022 Brilacidin Scientific Poster on Innovation Pharmaceuticals’ Brilacidin to be Presented at 2022 Chemical and Biological Defense Science & Technology Conference
Guest User October 4, 2022 Brilacidin Innovation Pharmaceuticals Announces Publication of Scientific Article on the Antifungal Activity of Brilacidin
Guest User September 15, 2022 Brilacidin New In Vitro Data Supporting the Broad-Spectrum Antiviral Activity of Innovation Pharmaceuticals’ Brilacidin Presented at 2022 Military Health System Research Symposium
Guest User August 5, 2022 Brilacidin Innovation Pharmaceuticals Announces NIH/NIAID-Affiliated Researchers to Evaluate Brilacidin’s Treatment Potential Against Monkeypox
Guest User July 22, 2022 Brilacidin Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical’s Brilacidin as a Novel Oral Mucositis Drug Candidate
Guest User June 28, 2022 Brilacidin Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium
Guest User June 23, 2022 Brilacidin Innovation Pharmaceuticals Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing by NIH/NIAID-Sponsored and Rutgers University Researchers
Guest User March 15, 2022 Brilacidin, Corporate Innovation Pharmaceuticals Announces Publication of Peer-Review Article in the Journal of Medical Virology on Anti-Coronavirus Properties of Brilacidin
Guest User March 7, 2022 Brilacidin, Corporate Innovation Pharmaceuticals Reports Additional Findings Based on Review of Brilacidin Phase 2 COVID-19 Trial Results and Compassionate Use Cases
Guest User December 7, 2021 Corporate, Brilacidin Innovation Pharmaceuticals Analyzing Full Dataset for Its Brilacidin COVID-19 Clinical Trial; Company Evaluating New Pipeline Opportunities for 2022
Guest User November 18, 2021 Brilacidin Innovation Pharmaceuticals Provides Brilacidin Program Update
Guest User November 12, 2021 Brilacidin Innovation Pharmaceuticals Conducting Full Data Analysis of Phase 2 Brilacidin COVID-19 Trial Results to Support Brilacidin’s Potential Inclusion in Government-Sponsored COVID-19 Trials
Guest User November 11, 2021 Brilacidin Innovation Pharmaceuticals Announces Topline Results from Phase 2 Clinical Trial of Brilacidin for COVID-19
Guest User November 3, 2021 Brilacidin Database Lock Completed for Innovation Pharmaceuticals’ Phase 2 Clinical Trial of Brilacidin for COVID-19
Guest User October 25, 2021 Brilacidin Innovation Pharmaceuticals’ COVID-19 Clinical Trial Topline Results Anticipated to Be Reported the Week of November 8th
Guest User September 23, 2021 Brilacidin Innovation Pharmaceuticals Provides Update on COVID-19 Clinical Trial, Compassionate Use Requests and Research into Brilacidin’s Broad-Spectrum Antiviral Properties
